[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-350348-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-350348-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","tedizolid-targets-aqp9-jakstat-axis-to-suppress-metastatic-progression-in-clear-cell-renal-cell-carcinoma-mechanism-and-therapeutic-implications","Tedizolid Targets AQP9-JAK/STAT Axis to Suppress Metastatic Progression in Clear Cell Renal Cell Carcinoma - Mechanism and Therapeutic Implications","","Metastasis is a primary driver of poor outcomes in clear cell renal cell carcinoma (ccRCC), yet the role of Aquaporin-9 (AQP9) in this process remains unclear. This study investigates AQP9 function, clinical significance, and therapeutic potential in ccRCC. AQP9 expression is analyzed using TCGA and validated in tissues and cell lines by Western blot. Functional assays, bioinformatics, and rescue experiments assess JAK/STAT involvement and epithelial–mesenchymal transition, while virtual screening, docking, and CETSAs identify tedizolid as a candidate AQP9 inhibitor.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/tedizolid-targets-aqp9-jakstat-axis-to-suppress-metastatic-progression-in-clear-cell-renal-cell-carcinoma-mechanism-and-therapeutic-implications/350348/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/tedizolid-targets-aqp9-jakstat-axis-to-suppress-metastatic-progression-in-clear-cell-renal-cell-carcinoma-mechanism-and-therapeutic-implications/350348.png","ImageObject",300,407,{"name":42,"@type":43},"Cart","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the study’s main goal regarding AQP9 in ccRCC?","Question",{"text":63,"@type":64},"To determine AQP9’s function and clinical significance in ccRCC metastasis, and evaluate its therapeutic potential as a target.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How is tedizolid connected to AQP9 and the JAK/STAT pathway?",{"text":68,"@type":64},"Tedizolid is identified as a potential AQP9 inhibitor and is shown to directly bind AQP9, reversing AQP9-driven malignant phenotypes and suppressing JAK/STAT signaling in vitro and in vivo.",{"name":70,"@type":61,"acceptedAnswer":71},"What is the proposed mechanism linking AQP9 to metastasis in ccRCC?",{"text":72,"@type":64},"AQP9 promotes metastasis through the JAK/STAT–EMT axis, where JAK/STAT activation supports epithelial–mesenchymal transition and enhances malignant behaviors.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},350348,1790219169,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},18829141979164,"https://eur-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Article  \nTedizolid Targets AQP9-JAK/STAT Axis to Suppress Metastatic Progression in Clear Cell Renal Cell Carcinoma: Mechanism and Therapeutic Implications  \nKexin Qu 1,†, Tianya Zhang 2,†, Rui Wang 1, Yingwei Bi 1, Jiacheng Jin 1, Yuxin Liu 1, Bolin Yi 1, Liang Zhu 3,* and Jianbo Wang 1, *  \nAcademic Editor: Noemi Monti  \nReceived: 13 April 2026  \nRevised: 2 May 2026  \nAccepted: 7 May 2026  \nPublished: 9 May 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Department of Urology, The First Affiliated Hospital of Dalian Medical University, Dalian 116011, China; [qkx3141@163.com](qkx3141@163.com) (K.Q.); [leynad1214@hotmail.com](leynad1214@hotmail.com) (R.W.); [biyingwei_@outlook.com](biyingwei_@outlook.com) (Y.B.); [jiachengjin.med@gmail.com](jiachengjin.med@gmail.com) (J.J.); [19845733936@163.com](19845733936@163.com) (Y.L.); [yibl@dmu.edu.cn](yibl@dmu.edu.cn) (B.Y.)  \n2 Department of Clinical Laboratory, The First Affiliated Hospital of Dalian Medical University, Dalian 116011, China; [zhangty01@dmu.edu.cn](zhangty01@dmu.edu.cn)  \n3 Advanced Institute for Medical Sciences, Dalian Medical University, Dalian 116011, China  \n* Correspondence: [zhuliang0210@sina.com](zhuliang0210@sina.com) (L.Z.); [wangjianbo@dmu.edu.cn](wangjianbo@dmu.edu.cn) (J.W.)† These authors contributed equally to this work.  \nAbstract  \nMetastasis is a primary driver of poor outcomes in clear cell renal cell carcinoma (ccRCC), yet the role of Aquaporin-9 (AQP9) in this process remains unclear. This study aimed to investigate the function, clinical significance, and therapeutic potential of AQP9 in ccRCC. AQP9 expression was analyzed using TCGA data and validated in human tissues and cell lines via Western blot. Functional assays assessed malignant behaviors, while bioinformatics and rescue experiments explored the involvement of the JAK/STAT pathway and epithelial–mesenchymal transition (EMT) . Virtual screening, molecular docking, and cellular thermal shift assays (CETSAs) were employed to identify Tedizolid as a potential AQP9 inhibitor, followed by functional validation in vitro and in a xenograft model. AQP9 was significantly upregulated in ccRCC and associated with poor prognosis. The knockdown of AQP9 suppressed proliferation, migration, invasion, and EMT, whereas its overexpression promoted these effects by activating the JAK/STAT pathway. Tedizolid bound directly to AQP9, inhibited cell viability, reversed AQP9-induced malignant phenotypes, and suppressed JAK/STAT signaling both in vitro and in vivo. In conclusion, AQP9 promotes ccRCC metastasis through the JAK/STAT-EMT axis and represents a potential prognostic biomarker and therapeutic target. Tedizolid, identified as a novel AQP9 inhibitor, offers a promising repurposed strategy for ccRCC treatment.  \nKeywords: Aquaporin-9; clear cell renal cell carcinoma; metastasis; JAK/STAT pathway; drug repurposing; tedizolid  \n1. Introduction  \nRenal cell carcinoma (RCC), a diverse group of cancers derived from renal tubular epithelial cells, represents the third most prevalent malignancy of the urinary system, following prostate and bladder cancers [1], and its global incidence continues to rise [2] . Among all RCC’s pathological types, clear cell RCC (ccRCC) has the biggest proportion, approximately occupying up to 75% of RCCs [3]. Although early-stage ccRCC can generally achieve a favorable prognosis through surgical treatment, about 20–40% of patients with localized tumors eventually experience distant metastases post-surgery [4] . Furthermore,  \naround 17% of ccRCC patients have already developed metastasis upon initial diagnosis; the five-year survival rate here is merely 12%, which shows that metastasis is one of the reasons why treatment fails and patients die [5] . Over recent years, immunotherapy and targeted therapy have been adopt","cbCaigtV5YWsHZx0","https://ap.wps.com/l/cbCaigtV5YWsHZx0","pdf",12928474,28,"English","# Introduction\n## Background on renal cell carcinoma and ccRCC\n## EMT as a key step in metastasis\n## Role and upstream regulation of the JAK/STAT pathway","[{\"question\":\"What is the study’s main goal regarding AQP9 in ccRCC?\",\"answer\":\"To determine AQP9’s function and clinical significance in ccRCC metastasis, and evaluate its therapeutic potential as a target.\"},{\"question\":\"How is tedizolid connected to AQP9 and the JAK/STAT pathway?\",\"answer\":\"Tedizolid is identified as a potential AQP9 inhibitor and is shown to directly bind AQP9, reversing AQP9-driven malignant phenotypes and suppressing JAK/STAT signaling in vitro and in vivo.\"},{\"question\":\"What is the proposed mechanism linking AQP9 to metastasis in ccRCC?\",\"answer\":\"AQP9 promotes metastasis through the JAK/STAT–EMT axis, where JAK/STAT activation supports epithelial–mesenchymal transition and enhances malignant behaviors.\"}]","Tedizolid Targets AQP9-JAK/STAT Axis to Suppress Metastatic Progression in Clear Cell Renal Cell Carcinoma - Mechanism and Therapeutic Implications | PDF",1790088578,71,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f81fa57c6c9449645cdfe6d9ad2679d3.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/97a5d1b9adfba8aca3eab1362a5381b6.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d92020f5b1d00ed80927aa9894035ef9.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/29bcee559b72dadc745d9181fc51fd63.webp",980,1385]